https://www.selleckchem.com/products/ala-gln.html
Overall, the approved infliximab biosimilar SB2 is safe and effective in clinical practice across licensed indications. The available analytical and clinical data support the equivalence of SB2 to the reference product across approved indications. This is further supported by emerging real-world evidence, particularly in extrapolated indications such as inflammatory bowel disease for both infliximab-naïve patients and patients already established on infliximab switching to SB2. Switching from originator or biosimilar infliximab to SB2 i
Like
Comment
Share
